to change the intellectual property rights over these vaccines. the question in the short run is manufacture. you have got to have the capacity to manufacture and present macro seem to be acknowledging, as prime minister johnson did, that in the short term at least it is going to have to be a case that you produce the vaccines in developed countries and get them out as fast as humanly possible to developing but in the medium to longer term you need to have more manufacturers in africa and other continents. manufacturers in africa and other continents- continents. there has been a disagreement continents. there has been a disagreement over continents. there has been a disagreement over whether i continents. there has been a| disagreement over whether to continents. there has been a - disagreement over whether to waive the patents. there are some who say that it the patents. there are some who say thatitis the patents. there are some who say that it is not as simple as that. they po